CoChat

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy

Open access
Ming, Zi‐He, Zhang, Yong‐Qu, Song, Liang, Chen, Min, Lin, Lin‐Ling, He, Yue‐Yang, Liu, Wan‐Ling, Zhu, Yuan‐Yuan, Zhang, Yun, Zhang, Guo‐Jun · 2024 · Advanced Science

Abstract

Radiotherapy demonstrates a synergistic effect with immunotherapy by inducing a transformation of “immune cold” tumors into “immune hot” tumors in triple negative breast cancer (TNBC). Nevertheless, the effectiveness of immunotherapy is constrained by low expression of tumor‐exposed antigens, inadequate inflammation, and insufficient tumor infiltrating lymphocyte (TILs). To address this predicament, novel lutecium‐based rare earth nanoparticles (RENPs) are synthesized with the aim of amplifying radiation effect and tumor immune response. The nanoprobe is characterized by neodymium‐based down‐conversion fluorescence, demonstrating robust photostability, biocompatibility, and targetability. The conjugation of RENPs with a CXCR4 targeted drug enables precise delineation of breast tumors using a near‐infrared imaging system and improves radiation efficacy via lutetium‐based radio‐sensitizer in vivo. Furthermore, the study shows a notable enhancement of immune response through the induction of immunogenic cell death and recruitment of TILs, resulting in the inhibition of tumor progression both in vitro and in vivo models following the administration of nanoparticles. Hence, the novel multifunctional nanoprobes incorporating various lanthanide elements offer the potential for imaging‐guided tumor delineation, radio‐sensitization, and immune activation post‐radiation, thus presenting an efficient radio‐immunotherapeutic approach for TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/advs.202309992

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Schematic illustration of the RENPs for precise guidance and sensitization of radiotherapy in synergism with ICT.
Scheme 1 Schematic illustration of the RENPs for precise guidance and sensitization of radiotherapy in synergism with ICT.CC BY · PubMed Central
Figure 1 Characterization of RENPs. A) Schematic diagram of probe synthesis. B) HAADF‐STEM image of core‐shell structure in RENPs and corresponding Nd/Yb/Lu/Na elemental mapping. C) DLS analysis of hydrodynamic size distribution of RENPs‐OA. D) Fluorescence emission spectra of RENPs. The left insert image was RENPs while the right one is DW of NIR‐II fluorescence imaging. E) Stability of RENPs and ICG in different solution including DW, 10% FBS and 5% GS under continuous laser irradiation. F) NIR‐II fluorescence images of RENPs following the increase of the thickness of 1% intralipid. Scale bar: 50 nm.
Figure 1 Characterization of RENPs. A) Schematic diagram of probe synthesis. B) HAADF‐STEM image of core‐shell structure in RENPs and corresponding Nd/Yb/Lu/Na elemental mapping. C) DLS analysis of hydrodynamic size distribution of RENPs‐OA. D) Fluorescence emission spectra of RENPs. The left insert image was RENPs while the right one is DW of NIR‐II fluorescence imaging. E) Stability of RENPs and ICG in different solution including DW, 10% FBS and 5% GS under continuous laser irradiation. F) NIR‐II fluorescence images of RENPs following the increase of the thickness of 1% intralipid. Scale bar: 50 nm.CC BY · PubMed Central
Figure 2 In vitro targeted aggregation of RENPs. A) Expression of CXCR4 in BRCA based on breast cancer subclasses in TCGA samples. B) Western blot analysis of CXCR4 expression level in different cell lines. The numbers above the black box are quantitative data, which represent CXCR4 expression/GAPDH expression. C) Flow cytometry of MCF‐10A and 4T1 cells incubated with RENPs and E) corresponding quantified of mean fluorescence intensities (MFI) (n = 3). D) Representative fluorescence microscope scanning of 4T1 cell crawling after incubated with RENPs‐control and RENPs, one group incubated with AMD3100 ahead to block CXCR4 and F) corresponding mean MFI (n = 5). Scale bar: 50 µm. **P < 0.01, ****P < 0.0001.
Figure 2 In vitro targeted aggregation of RENPs. A) Expression of CXCR4 in BRCA based on breast cancer subclasses in TCGA samples. B) Western blot analysis of CXCR4 expression level in different cell lines. The numbers above the black box are quantitative data, which represent CXCR4 expression/GAPDH expression. C) Flow cytometry of MCF‐10A and 4T1 cells incubated with RENPs and E) corresponding quantified of mean fluorescence intensities (MFI) (n = 3). D) Representative fluorescence microscope scanning of 4T1 cell crawling after incubated with RENPs‐control and RENPs, one group incubated with AMD3100 ahead to block CXCR4 and F) corresponding mean MFI (n = 5). Scale bar: 50 µm. **P < 0.01, ****P < 0.0001.CC BY · PubMed Central
Figure 3 RT sensitization and DCs maturation by RENPs plus RT in vitro. A) Viability of 4T1 cells incubated with RENPs in different concentration under different dose of X‐ray irradiation and B) corresponding quantified of cell viability treated with 50 µg mL−1 RENPs under 6 Gy. C) Colony formation assay of 4T1 cells after various treatments. D) Fluorescent images of intracellular ROS generation in 4T1 cells after different treatments. E) Flow cytometry analysis of apoptosis rates in 4T1 cells after different treatments. F) Flow cytometry analysis of surface expression of CD80+ CD86+ on DCs after different treatments. G) Statistical analysis of mean fluorescence intensity in (D). H) Statistical analysis of apoptotic cells in (E). I) Statistical analysis of mature DCs ratio in (F). Data were given as mean ± S.D. Scale bar: 25 µm. **P < 0.01, ***P < 0.001, ****P < 0.0001, n = 3.
Figure 3 RT sensitization and DCs maturation by RENPs plus RT in vitro. A) Viability of 4T1 cells incubated with RENPs in different concentration under different dose of X‐ray irradiation and B) corresponding quantified of cell viability treated with 50 µg mL−1 RENPs under 6 Gy. C) Colony formation assay of 4T1 cells after various treatments. D) Fluorescent images of intracellular ROS generation in 4T1 cells after different treatments. E) Flow cytometry analysis of apoptosis rates in 4T1 cells after different treatments. F) Flow cytometry analysis of surface expression of CD80+ CD86+ on DCs after different treatments. G) Statistical analysis of mean fluorescence intensity in (D). H) Statistical analysis of apoptotic cells in (E). I) Statistical analysis of mature DCs ratio in (F). Data were given as mean ± S.D. Scale bar: 25 µm. **P < 0.01, ***P < 0.001, ****P < 0.0001, n = 3.CC BY · PubMed Central
Figure 4 Target effect and RT sensitization effect of RENPs in subcutaneous tumor bearing mouse. A) Bright images and NIR fluorescence images of representative mice injected with RENPs‐control and RENPs at different time points post‐injection. The red/white dotted ellipses indicate the tumor position. B) The SNRs of tumor‐bearing mice injected RENPs‐control and RENPs at different time points. (n = 3) C,D) Photographs of mice and excised tumor after different treatments. E) Average radiance of tumor bioluminescence after different treatments. F) Tumor volume of transplanted tumor after different treatments. G) Body weight of mice after different treatments. Data are presented as the mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 4 Target effect and RT sensitization effect of RENPs in subcutaneous tumor bearing mouse. A) Bright images and NIR fluorescence images of representative mice injected with RENPs‐control and RENPs at different time points post‐injection. The red/white dotted ellipses indicate the tumor position. B) The SNRs of tumor‐bearing mice injected RENPs‐control and RENPs at different time points. (n = 3) C,D) Photographs of mice and excised tumor after different treatments. E) Average radiance of tumor bioluminescence after different treatments. F) Tumor volume of transplanted tumor after different treatments. G) Body weight of mice after different treatments. Data are presented as the mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 5 The antitumor immune response induced by combination therapy. A) Design of combination therapy in mouse. Group A received PBS. Group B received PBS + ICT. Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT. B) Images of mice and excised tumor after different treatments. C) Kaplan‐Meier analysis in survival of different groups. D) Average radiance of tumor bioluminescence after different treatments. E) Primary tumor volume after different treatments. F) Distal tumor volume after different treatments. G) CD8+ and CD4+ T cells proportions in distal tumors and spleen evaluated by flow cytometry. H,I) Quantitative analysis of mean fluorescence intensity in (G). J–M) Concentration of IL‐6, IFN‐γ, IL‐12p70, and TNF‐α cytokines in mouse serum tested by ELISAs. Data are presented as the mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 5 The antitumor immune response induced by combination therapy. A) Design of combination therapy in mouse. Group A received PBS. Group B received PBS + ICT. Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT. B) Images of mice and excised tumor after different treatments. C) Kaplan‐Meier analysis in survival of different groups. D) Average radiance of tumor bioluminescence after different treatments. E) Primary tumor volume after different treatments. F) Distal tumor volume after different treatments. G) CD8+ and CD4+ T cells proportions in distal tumors and spleen evaluated by flow cytometry. H,I) Quantitative analysis of mean fluorescence intensity in (G). J–M) Concentration of IL‐6, IFN‐γ, IL‐12p70, and TNF‐α cytokines in mouse serum tested by ELISAs. Data are presented as the mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 6 H&E staining, cleaved‐caspase 3, Ki 67, CXCR4 and PD‐L1 IHC staining images of tumor slices after various treatments. A) Primary tumor slices of Cleaved‐caspase 3, Ki 67, CXCR4, and PD‐L1 expression on tumor cells. B) Distal tumor slices of Cleaved‐caspase 3, Ki 67, CXCR4, and PD‐L1 expression on tumor cells. Scale bar: 50 µm. Group A received PBS. Group B received PBS + ICT. Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.
Figure 6 H&E staining, cleaved‐caspase 3, Ki 67, CXCR4 and PD‐L1 IHC staining images of tumor slices after various treatments. A) Primary tumor slices of Cleaved‐caspase 3, Ki 67, CXCR4, and PD‐L1 expression on tumor cells. B) Distal tumor slices of Cleaved‐caspase 3, Ki 67, CXCR4, and PD‐L1 expression on tumor cells. Scale bar: 50 µm. Group A received PBS. Group B received PBS + ICT. Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 14

Metadata

Authors
Ming, Z., Zhang, Y., Song, L., Chen, M., Lin, L., He, Y., Liu, W., Zhu, Y., Zhang, Y., & Zhang, G.
Affiliations
  • Xiamen University (CN)
  • Chinese Academy of Sciences (CN)
  • Cancer Center and Department of Breast and Thyroid Surgery Xiang'an Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian 361104 China
Corresponding author
  • Zhang, Yun
  • Zhang, Guo‐Jun
Venue
Advanced Science
Publisher
Wiley
Published
2024-05-22
Volume
11
Issue
29
Pages
e2309992-e2309992
ISSN
2198-3844 (ISSN-L)
OpenAlex
W4398215405
Cited by
13
References
45
Citations by year
2026: 4 · 2025: 8 · 2024: 1
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fujian Science and Technology Innovation Laboratory for Optoelectronic Information of China (2020ZZ114)
  • National Natural Science Foundation of China (62105333, 32171363, 82172009)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
triple-negative breast cancer, rare earth nanoparticles, lutetium, neodymium, radioimmunotherapy, radiosensitization, near-infrared imaging, tumor delineation, tumor-infiltrating lymphocytes, immunogenic cell death, lanthanide elements
MeSH terms
Animals, Disease Models, Animal, Female, Humans, Metals, Rare Earth, Radioimmunotherapy, Cell Line, Tumor, Mice, Nanoparticles, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.